<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Perm Medical Journal</journal-id><journal-title-group><journal-title xml:lang="en">Perm Medical Journal</journal-title><trans-title-group xml:lang="ru"><trans-title>Пермский медицинский журнал (сетевое издание "Perm medical journal")</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0136-1449</issn><issn publication-format="electronic">2687-1408</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">472100</article-id><article-id pub-id-type="doi">10.17816/pmj40265-77</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Methods of diagnostics and technologies</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Методы диагностики и технологии</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Associations between indicators of new semi-quantitative express-test for procalcitonin and indicators of saturation in patients with community-acquired pneumonia</article-title><trans-title-group xml:lang="ru"><trans-title>Ассоциации показателей нового полуколичественного экспресс-теста на прокальцитонин и показателей сатурации у пациентов с внебольничной пневмонией</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0207-7063</contrib-id><name-alternatives><name xml:lang="en"><surname>Tsygankova</surname><given-names>Oksana V.</given-names></name><name xml:lang="ru"><surname>Цыганкова</surname><given-names>Оксана В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor of the Department of Emergency Therapy with Endocrinology and Occupational Pathology, senior researcher of the Laboratory of Clinical Biochemical and Hormonal Researches of Therapeutic Diseases</p></bio><bio xml:lang="ru"><p>доктор медицинских наук, профессор кафедры неотложной терапии с эндокринологией и профпатологией, старший научный сотрудник лаборатории клинических биохимических и гормональных исследований терапевтических заболеваний</p></bio><email>oksana_c.nsk@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bairamova</surname><given-names>S. S.</given-names></name><name xml:lang="ru"><surname>Байрамова</surname><given-names>С. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>junior researcher, Laboratory of Emergency Therapy</p></bio><bio xml:lang="ru"><p>младший научный сотрудник лаборатории неотложной терапии</p></bio><email>oksana_c.nsk@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4601-6203</contrib-id><name-alternatives><name xml:lang="en"><surname>Nikolaev</surname><given-names>K. Yu.</given-names></name><name xml:lang="ru"><surname>Николаев</surname><given-names>К. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor, Head of the Laboratory of Emergency Therapy</p></bio><bio xml:lang="ru"><p>доктор медицинских наук, профессор, заведующий лабораторией неотложной терапии</p></bio><email>oksana_c.nsk@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Institute of Therapy and Preventive Medicine – Branch of the Federal Research Center “Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences”</institution></aff><aff><institution xml:lang="ru">Научно-исследовательский институт терапии и профилактической медицины – филиал Института цитологии и генетики Сибирского отделения Российской академии наук</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Novosibirsk State Medical University</institution></aff><aff><institution xml:lang="ru">Новосибирский государственный медицинский университет</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-06-02" publication-format="electronic"><day>02</day><month>06</month><year>2023</year></pub-date><volume>40</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>65</fpage><lpage>77</lpage><history><date date-type="received" iso-8601-date="2023-06-02"><day>02</day><month>06</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-06-02"><day>02</day><month>06</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Эко-Вектор</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://permmedjournal.ru/PMJ/article/view/472100">https://permmedjournal.ru/PMJ/article/view/472100</self-uri><abstract xml:lang="en"><p><bold>Objective</bold><bold>. </bold>To evaluate the associations between the indicators of a new semi-quantitative express-test for procalcitonin and saturation levels in hospitalized patients with community-acquired pneumonia.</p> <p>Due to a high rate of growth of the incidence of severe community-acquired pneumonia, which leads to disability of the working population and claims thousands of lives, there is a need for early verification of the severity degree and a timely initiation of treatment. Traditional clinical, radiologic, laboratory and bacteriological criteria for inflammatory reactions (fever, increased pulmonary infiltration and leukocytosis, detection of potential pathogens in sputum or hemocultures) are not specific for pneumonia. Similar clinical and radiologic manifestations can also be noted in other pathological conditions, for example, in atelectasis of the lung, lung infarction, congestive heart failure, as well as acute respiratory distress syndrome. In this regard, the study of new diagnostic markers of community-acquired pneumonia is an actual direction in modern therapeutic diagnostics. Being a fast and highly sensitive method, the express test for procalcitonin can be a valuable predictive marker for the severe course of community-acquired pneumonia. Of interest is the relationship of procalcitonin with an indicator reflecting the presence of respiratory failure – the level of saturation.</p> <p><bold>Materials</bold><bold> and methods. </bold>A single-stage comparative study involved 123 patients admitted to the hospital with a confirmed diagnosis of community-acquired pneumonia. On the first day after admission to the hospital, all patients underwent a general clinical examination, an overview X-ray of the chest organs, and determination of the plasma procalcitonin level using a semi-quantitative express-test as well as the saturation level. According to the results of the examination, the patients were divided into two groups: patients with saturation &lt; 94 % (<italic>n</italic>=43), and patients with saturation ≥ 94 % (<italic>n</italic>=80). The group of patients with saturation values &lt; 94 % consisted of 23 (53.5 %) women and 20 (46.5 %) men. The group of patients with saturation values ≥ 94 % consisted of 42 (52.5 %) women and 38 (47.5 %) men. The mean age of the patients was 56.7±19.1 and 45.6±20.7 (<italic>M</italic>±<italic>SD</italic>) years, respectively, <italic>p</italic>=0.005. Statistical processing of the obtained data was carried out using the SPSS 13.0 software package.</p> <p><bold>Results</bold><bold>. </bold>Patients with low saturation values (&lt; 94 %) had higher heart rate (<italic>p</italic>=0.001) and respiratory rate (<italic>p</italic>=0.001), and the levels of erythrocytes (<italic>p</italic>=0.001), hemoglobin (<italic>p</italic>=0.003) and albumin (<italic>p</italic>=0.001) were significantly lower than in patients with higher saturation levels ≥ 94 %. For patients with signs of respiratory failure and saturation indices &lt; 94 %, a more pronounced increase in the level of express-test for procalcitonin was characteristic (<italic>p</italic>=0.001). According to regression analysis, the express-test for procalcitonin ≥ 2 ng/ml by 13.8 % (CI 1.5–131.3), age by 3 %, and heart rate by 11 % increase the risk of low saturation in patients with community-acquired pneumonia.</p> <p><bold>Conclusion</bold><bold>. </bold>Low values of blood oxygen saturation &lt; 94 % in hospitalized patients with community-acquired pneumonia are directly associated with high values of the new semi-quantitative express-test for procalcitonin (more than 2 ng/ml), that can be used for individual risk stratification.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель.</bold> Оценить ассоциации показателей нового полуколичественного экспресс-теста на прокальцитонин и уровней сатурации у госпитализированных пациентов с внебольничной пневмонией.</p> <p>В связи с высокими темпами роста заболеваемости тяжелой внебольничной пневмонией, влекущей инвалидизацию трудоспособного населения и уносящей тысячи жизней, возникает потребность в ранней верификации степени тяжести и своевременном начале лечения. Традиционные клинические, рентгенологические, лабораторные и бактериологические критерии воспалительных реакций (лихорадка, нарастание легочной инфильтрации, лейкоцитоз, выявление в мокроте или гемокультурах потенциальных возбудителей) не являются специфичными для пневмонии. Сходные клинико-рентгенологические проявления могут также отмечаться при других патологических состояниях, например, при ателектазе, инфаркте легкого, застойной сердечной недостаточности, а также остром респираторном дистресс-синдроме.</p> <p>В связи с этим изучение новых диагностических маркеров внебольничной пневмонии является актуальным направлением в современной терапевтической диагностике. Являясь быстрым и высокочувствительным методом, экспресс-тест на прокальцитонин способен стать ценным прогностическим маркером тяжелого течения внебольничной пневмонии. Интерес вызывает связь прокальцитонина с показателем, ассоциированным с дыхательной недостаточностью – уровнем сатурации.</p> <p><bold>Материалы и методы. </bold>В одномоментном сравнительном исследовании участвовало 123 пациента, госпитализированных в стационар с подтвержденным диагнозом «внебольничная пневмония». В первые сутки с момента поступления всем пациентам проведено общеклиническое обследование, обзорная рентгенография органов грудной клетки, а также при помощи полуколичественного экспресс-теста определен уровень прокальцитонина плазмы и уровень сатурации. Пациенты были разделены на две группы: c сатурацией &lt; 94 % (<italic>n</italic>=43) и ≥ 94 % (<italic>n</italic>=80). Группа пациентов с меньшими показателями сатурации состояла из 23 (53,5 %) женщин и 20 (46,5 %) мужчин. Группа пациентов с показателями сатурации ≥ 94 % состояла из 42 (52,5 %) женщин и 38 (47,5 %) мужчин. Средний возраст включенных составил 56,7±19,1 и 45,6±20,7 г. (<italic>M</italic>±<italic>SD</italic>) соответственно, <italic>р</italic>=0,005. Статистическая обработка полученных данных проводилась с помощью пакета программ SPSS 13.0.</p> <p><bold>Результаты. </bold>У больных с низкими значениями сатурации (&lt; 94 %) отмечались более высокие показатели ЧСС (<italic>p=</italic>0,001) и ЧДД (<italic>p</italic>=0,001), а уровни эритроцитов (<italic>p</italic>=0,001), гемоглобина (<italic>р</italic>=0,003) и альбумина (<italic>р</italic>=0,001) были существенно ниже, чем у пациентов с более высокими показателями сатурации ≥ 94 %. Для больных с признаками дыхательной недостаточности и показателями сатурации &lt; 94 % характерным оказалось более выраженное повышение уровня экспресс-теста на прокальцитонин (<italic>р</italic>=0,001). По данным регрессионного анализа показатели экспресс-теста на прокальцитонин ≥ 2 нг/мл на 13,8 % (ДИ 1,5–131,3), возраст на 3 %, а ЧСС на 11 % повышают риск низкой сатурации у больных с внебольничной пневмонией.</p> <p><bold>Выводы. </bold>Низкие значения сатурации крови кислородом (&lt; 94 %) у госпитализированных пациентов с внебольничной пневмонией прямо ассоциированы с высокими значениями нового полуколичественного экспресс-теста на прокальцитонин (более 2 нг/мл), что может быть использовано для индивидуальной стратификации риска.</p></trans-abstract><kwd-group xml:lang="en"><kwd>procalcitonin</kwd><kwd>procalcitonin express-test</kwd><kwd>community-acquired pneumonia</kwd><kwd>saturation</kwd><kwd>respiratory distress</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>прокальцитонин</kwd><kwd>прокальцитонин экспресс-тест</kwd><kwd>внебольничная пневмония</kwd><kwd>сатурация</kwd><kwd>дыхательная недостаточность</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Naghavi M., Abajobir A.A., Abbafati C., Abbas K.M., Abd-Allah F., Abera S.F. et al. Global, regional and national age–sex specific mortality for 264 causes of death,1980–2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017; 390 (10100): 1151–1210. DOI: 10.1016/S0140-6736(17)32152-9.</mixed-citation><mixed-citation xml:lang="ru">Naghavi M., Abajobir A.A., Abbafati C., Abbas K.M., Abd-Allah F., Abera S.F. et al. Global, regional and national age–sex specific mortality for 264 causes of death,1980–2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017; 390 (10100): 1151–1210. DOI: 10.1016/S0140-6736(17) 32152-9.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Infekcionnaya zabolevaemost' v Rossijskoj Federacii za yanvar' – dekabr' 2018g. Rospo-trebnadzor: oficial'nyj sajt, available at: https:// rospotrebnadzor.ru/activities/statistical-materials/ statictic_details.php?ELEMENT_ID=11277</mixed-citation><mixed-citation xml:lang="ru">Инфекционная заболеваемость в Российской Федерации за январь – декабрь 2018 г. Роспотребнадзор: официальный сайт, available at: https://rospotrebnadzor.ru/activities/statistical-materials/statictic_details.php?ELEMENT_ID=11277.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><mixed-citation>Cavallazzi R., Furmanek S., Arnold F.W., Beavin L.A., Wunderink R.G., Niederman M.S., Ramirez J.A. The Burden of Community-Acquired Pneumonia Requiring Admission to ICU in the United States. Chest. 2020; 158 (3): 1008–1016. DOI: 10.1016/j.chest.2020.03.051.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Peyrani P., Arnold F.W., Bordon J., Furmanek S., Luna C.M., Cavallazzi R., Ramirez J. Incidence and Mortality of Adults Hospitalized With Community-Acquired Pneumonia According to Clinical Course. Chest. 2020; 157 (1): 34–41. DOI: 10.1016/j.chest.2019.09.022.</mixed-citation></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Bayramova S.S., Tsygankova O.V., Nikolaev K.Y. New semi-quantitative rapid test for procalcitonin in hospitalized patients with community-acquired pneumonia of varying severity. RMZh. Medicinskoe obozrenie. 2022; 6 (7): 344–351. DOI: 10.32364/2587-6821-2022-6-7-344-351 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Байрамова С.С., Цыганкова О.В., Николаев К.Ю. Новый полуколичественный экспресс-тест на прокальцитонин у госпитализированных пациентов с внебольничной пневмонией различной степени тяжести. РМЖ. Медицинское обозрение 2022; 6 (7): 344–351. DOI: 10.32364/2587-6821-2022-6-7-344-351.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><mixed-citation>Patel S. Calculated decisions: CURB-65 score for pneumonia severity. Emerg Med Pract. 2021; 23 (2): CD1–CD2.</mixed-citation></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">L Jekarl D.W., Lee S., Kim M., Kim Y., Woo S.H., Lee W.J. Procalcitonin as a prognostic marker for sepsis based on SEPSIS-3. J Clin Lab Anal. 2019; 33 (9): e22996. DOI: 10.1002/jcla.22996.</mixed-citation><mixed-citation xml:lang="ru">Jekarl D.W., Lee S., Kim M., Kim Y., Woo S.H., Lee W.J. Procalcitonin as a prognostic marker for sepsis based on SEPSIS-3. J Clin Lab Anal. 2019; 33 (9): e22996. DOI: 10.1002/jcla.22996.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><mixed-citation>Covino M., Manno A., De Matteis G., Taddei E., Carbone L., Piccioni A., Simeoni B., Fantoni M., Franceschi F., Murri R. Prognostic Role of Serum Procalcitonin Measurement in Adult Patients Admitted to the Emergency Department with Fever. Antibiotics (Basel). 2021; 10 (7): 788. DOI: 10.3390/antibiotics10070788.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Pierrakos C., Velissaris D., Bisdorff M., Marshall J.C., Vincent J.L. Biomarkers of sepsis: time for a reappraisal. Crit Care. 2020; 24 (1): 287. DOI: 10.1186/s13054-020-02993-5.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Schuetz P., Mueller B. Procalcitonin to Guide Antibiotic Decisions-Reply. JAMA 2018; 320: 406–407.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Schuetz P., Branche A., Mueller B. Low procalcitonin, community acquired pneumonia, and antibiotic therapy–Authors’ reply. Lancet Infect. Dis. 2018; 18: 497–498.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Ito A., Ishida T. Diagnostic markers for community-acquired pneumonia. Ann Transl Med. 2020; 8 (9): 609. DOI: 10.21037/atm.2020.02.182.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Finch S., Keir H.R., Dicker A.J., Chalmers J.D. The past decade in bench research into pulmonary infectious diseases: What do clinicians need to know? Respirology. 2017; 22 (6): 1062–1072. DOI: 10.1111/resp.13106.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Pantzaris N.D., Spilioti D.X., Psaromyalou A., Koniari I., Velissaris D. The Use of Serum Procalcitonin as a Diagnostic and Prognostic Biomarker in Chronic Obstructive Pulmonary Disease Exacerbations: A Literature Review Update. J Clin Med Res. 2018; 10 (7): 545–551. DOI: 10.14740/jocmr3458w.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Velissaris D., Zareifopoulos N., Lagadinou M., Platanaki C., Tsiotsios K., Stavridis E.L., Kasartzian D.I., Pierrakos C., Karamouzos V. Procalcitonin and sepsis in the Emergency Department: an update. Eur Rev Med Pharmacol Sci. 2021; 25 (1): 466–479. DOI: 10.26355/ eurrev_202101_24416.</mixed-citation></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Bohuon C. A brief history of procalcitonin. Intensive Care Med. 2000; 26 (2): S146–7. DOI: 10.1007/BF02900727.</mixed-citation><mixed-citation xml:lang="ru">Bohuon C. A brief history of procalcitonin. Intensive Care Med. 2000; 26 (2): S146-7. DOI: 10.1007/BF02900727.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Karakioulaki M., Stolz D. Biomarkers in Pneumonia-Beyond Procalcitonin. International Journal of Molecular Sciences 2019; 20 (8): 2004. DOI: 10.3390/ijms20082004.</mixed-citation><mixed-citation xml:lang="ru">Karakioulaki M., Stolz D. Biomarkers in Pneumonia-Beyond Procalcitonin. International Journal of Molecular Sciences. 2019; 20 (8): 2004. DOI: 10.3390/ijms20082004.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><mixed-citation>Baek M.S., Park S., Choi J.H., Kim C.H., Hyun I.G. Mortality and Prognostic Prediction in Very Elderly Patients with Severe Pneumonia. J Intensive Care Med. 2020; 35 (12): 1405–1410. DOI: 10.1177/0885066619826045.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Mierzchała-Pasierb M., Lipińska-Gediga M. Sepsis diagnosis and monitoring – procalcitonin as standard, but what next? Anaesthesiol Intensive Ther. 2019; 51 (4): 299–305. DOI: 10.5114/ait.2019.88104.</mixed-citation></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Kyriazopoulou E., Liaskou-Antoniou L., Adamis G. et al. Procalcitonin to Reduce Long-Term Infection-associated Adverse Events in Sepsis. A Randomized Trial. Am J Respir Crit Care Med. 2021; 203 (2): 202–210. DOI: 10.1164/rccm.202004-1201OC (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Kyriazopoulou E., Liaskou-Antoniou L., Adamis G. et al. Procalcitonin to Reduce Long-Term Infection-associated Adverse Events in Sepsis. A Randomized Trial. Am J Respir Crit Care Med. 2021; 203 (2): 202–210. DOI: 10.1164/rccm.202004-1201OC.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Lazareva N.B., Zhuravleva M.V., Prokofiev A.B., Shikh E.V. Potential Possibilities of Monitoring the Procalcitonin Concentration During Antibacterial Therapy of Lower Respiratory Tract Infections. Antibiotiki i Khimioterapiya=Antibiotics and chemotherapy. 2018; 63 (1–2): 32–37. DOI: 10.24411/0235-2990-2018-00013.</mixed-citation><mixed-citation xml:lang="ru">Лазарева Н.Б., Журавлева М.В., Прокофьев А.Б., Ших Е.В. Потенциальные возможности мониторинга концентрации прокальцитонина при проведении антибактериальной терапии инфекций нижних дыхательных путей. Антибиотики и химиотерапия. 2018; 63 (1–2): 32–37. DOI: 10.24411/0235-2990-2018-00013.</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><mixed-citation>Frenzen F.S., Kutschan U., Meiswinkel N., Schulte-Hubbert B., Ewig S., Kolditz M. Admission lactate predicts poor prognosis independently of the CRB/CURB-65 scores in community-acquired pneumonia. Clin Microbiol Infect. 2018; 24 (3): 306.e1–306.e6. DOI: 10.1016/j.cmi.2017.07.007.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Torres A., Cilloniz C., Blasi F. et al. Burden of pneumococcal community-acquired pneumonia in adults across Europe: a literature review. Respir Med. 2018; 137: 6–13. DOI: 10.1016/j.rmed.2018.02.007.</mixed-citation></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Losier A., Dela Cruz Ch. New testing guidelines for community-acquired pneumonia. Current Opinion in Infectious Diseases. 2022; 35 (2): 128–132. DOI: 10.1097/ QCO.0000000000000824.</mixed-citation><mixed-citation xml:lang="ru">Losier A., Dela Cruz Ch. New testing guidelines for community-acquired pneumonia. Current Opinion in Infectious Diseases 2022; 35 (2): 128–132. DOI: 10.1097/QCO.0000000000000824.</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><mixed-citation>Gutbier B., Neuhauß A.K., Reppe K., Ehrler C., Santel A., Kaufmann J. et al. Prognostic and Pathogenic Role of Angiopoietin-1 and -2 in Pneumonia. Am J Respir Crit Care Med. 2018; 198 (2): 220–231. DOI: 10.1164/rccm.201708-1733OC.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Klouche K., Cristol J.P., Devin J., Gilles V., Kuster N., Larcher R. et al. Diagnostic and prognostic value of soluble CD14 subtype (Presepsin) for sepsis and community-acquired pneumonia in ICU patients. Ann Intensive Care. 2016; 6 (1): 59. DOI: 10.1186/s13613-016-0160-6.</mixed-citation></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Zhuang Y., Li W., Wang H., Peng H., Chen Y., Zhang X. et al. Predicting the Outcomes of Subjects With Severe Community-Acquired Pneumonia Using Monocyte Human Leukocyte Antigen-DR. Respir Care. 2015; 60 (11): 1635–42. DOI: 10.4187/respcare.03953.</mixed-citation><mixed-citation xml:lang="ru">Zhuang Y., Li W., Wang H., Peng H., Chen Y., Zhang X. et al. Predicting the Outcomes of Subjects With Severe Community-Acquired Pneumonia Using Monocyte Human Leukocyte Antigen-DR. Respir Care. 2015; 60 (11): 1635–1642. DOI: 10.4187/respcare.03953.</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">Nikolaev K.Yu., Tsygankova O.V., Bayramova S.S. Significance of the new semi-quantitative rapid procalcitonin test in determining the severity of community-acquired pneumonia. Medicinskij alfavit=Medical alphabet. 2020; (1): 11–13. DOI: 10.33667/2078-5631-2020-27-11-13 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Николаев К.Ю., Цыганкова О.В., Байрамова С.С. Значимость нового полуколичественного экспресс теста на прокальцитонин в определении тяжести внебольничной пневмонии. Медицинский алфавит 2020; (27): 11–13. DOI: 10.33667/2078-5631-2020-27-11-13.</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">Kochegarova E.Yu., Kolosov V.P. Prognostication of community-acquired pneumonia course. Byulleten' fiziologii i patologii dyhaniya=Bulletin Physiology and Pathology of Respiration. 2011; (40): 48–51, available at: https:// cyberleninka.ru/article/n/prognozirovanie-techeniya-vnebolnichnoy-pnevmonii (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Кочегарова Е.Ю., Колосов В.П. Прогнозирование течения внебольничной пневмонии. Бюллетень физиологии и патологии дыхания 2010; (37): 42–46 available at: https://cyberleninka.ru/article/n/prognozirovanie-techeniya-vnebolnichnoy-pnevmonii.</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">Grishin O.V., Grishin V.G. Clinical use of pulse oximetry in adults. Medicinskij alfavit=Medical alphabet. 2020; (25): 13–21. DOI: 10.33667/2078-5631-2020-25-13-21 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Гришин О.В., Гришин В.Г. Клиническое значение пульсоксиметрии у взрослых. Медицинский алфавит 2020; (25): 13–21. DOI: 10.33667/2078–5631–2020–25–13–21.</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><mixed-citation>Self W.H., Grijalva C.G., Williams D.J., Woodworth A., Balk R., Fakhran Sh. et al. Procalcitonin as an Early Marker of the Need for Invasive Respiratory or Vasopressor Support in Adults With Community-Acquired Pneumonia. Chest. 2016; 150 (4): 819–828. DOI: 10.1016/j.chest.2016.04.010.</mixed-citation></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">Wang Y., Zhang S., Li L. et al. The usefulness of serum procalcitonin, C-reactive protein, soluble triggering receptor expressed on myeloid cells 1 and Clinical Pulmonary Infection Score for evaluation of severity and prognosis of community-acquired pneumonia in elderly patients. Arch Gerontol Geriatr. 2019; 80: 53–57. DOI: 10.1016/j.archger.2018.10.005.</mixed-citation><mixed-citation xml:lang="ru">Wang Y., Zhang S., Li L. et al. The usefulness of serum procalcitonin, C-reactive protein, soluble triggering receptor expressed on myeloid cells 1 and Clinical Pulmonary Infection Score for evaluation of severity and prognosis of community-acquired pneumonia in elderly patients. Arch Gerontol Geriatr. 2019; 80: 53–7. DOI: 10.1016/j.archger.2018.10.005.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
